Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma

Current Medical Research and Opinion

Volumn 23, Issue 5, 2007, Pages 1147-1159

  Doull, Iolo ^a   Price, David ^b   Thomas, Mike ^b   Hawkins, Neil ^c   Stamuli, Eugena ^c   Tabberer, Maggie ^c   Gosden, Toby ^d   Rudge, Helen ^d  

^a CHILDREN S HOSPITAL FOR WALES   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ICON PLC   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Asthma; Cost effectiveness; Fluticasone salmeterol; Quality of life

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL;

ARTICLE; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; GROUPS BY AGE; HEALTH SERVICES RESEARCH; HUMAN; INHALER; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HEALTH SERVICES; HOSPITALS, STATE; HUMANS; MODELS, ECONOMETRIC; NEBULIZERS AND VAPORIZERS;

EID: 34249086592     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X187982     Document Type: Article

References (49)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health. National Heart, Lung and Blood Institute 2002; Publication No. 02-3659
2. Asthma UK. Where do we stand? Asthma in the UK today 2004
3. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination. Pharmacoeconomics 2003;21:951-89
4. National Asdima Campaign. Out in the open. A picture of asthma in the UK today 2002
5. Hoskins G, McCowan C, Neville R, et al. Risk factors and costs associated with an asthma attack. PharmacoEconomics and Outcomes News 2000;253:8
6. Vervloet D, Williams A, Lloyd A, Clark T. Costs of managing asdima as defined by a derived Asthma Control TestTM score in seven European countries. Eur Respir Rev 2006;15:17-23
7. Lloyd A, Price D, Brown R. The impact of asdima exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-27
8. British Thoracic Society. British Guideline on the Management of Asthma. Revised edn. November, 2005
9. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. J Allergy Clin Immunol 2001;108:39-46
10. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002;20:183-94
11. Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomediasone or budesonide for chronic asthma in adults and children. The Cochrane Database Syst Rev 2005; Issue 3: CD002310.pub3. DOI:10.1002/14651858. CD002310.pub3
12. Ni Chroinin M, Greenstone I, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev (Online: Update Software) 2007;1
13. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 mg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001;95:136-46 (SFCB3022)
14. van Noord JA, Lill H, Carillo Diaz T, et al. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500 meg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus in patients with moderate to severe asthma. Clin Drug Invest 2001;21:243-55 (SFCB3023)
15. Bateman ED, Bousehey H, Bousquet J, et al. Can Guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004;170:836-44 (SAM40027)
16. Hornik K. The R FAQ. http://CRAN.R-project.org/doc/FAQ/R-FAQ.html (accessed July 2006) ISBN 3-900051-08-9 2006
17. GSK. Clinical Trials Register. http://ctr.gsk.co.uk/Summary/ fluticasone_salmeterol/studylist.asp (accessed 30 April 2006) 2006
18. Aalbers R, Backer V, Kava T, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20:225-40
19. Fitzgerald J, Boulet L, Follows R. The CONCEPT trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005;27:393-406
20. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26:819-28
21. National Institute of Health and Clinical Excellence. Technology Appraisal Guidance No 10. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. http://www.nice.org.uk/ download.aspx?o=TA010guidance&template=download.aspx (accessed July 2006) 2000
22. National Institute of Health and Clinical Excellence. Technology Appraisal Guidance No 38. Inhaler devices for routine treatment of asthma in older children (aged 5-15 years). http://www.nice.org.uk/page.aspx?o= TA038guidance (accessed July 2006) 2002
23. Drug Tariff, http://www.drugtariff.com (accessed July 2006)
24. eMIMS. http://www.emims.net (accessed July 2006) 2006
25. Briggs AH, Bousquet J, Wallace MV, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006;61:531-6
26. Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference based condition-specific instruments: Converting AQLQ into EQ5D indices. Discussion paper 02/1 http://www.shef.ac.uk/ content/1/c6/01/87/47/DP0201.pdf (accessed July 2006) 2002
27. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996;9:120
28. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87
29. National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. April 2004
30. Higgins J, Green S (editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons Ltd
31. Bjermer L. Evidence-based recommendations or 'show me the patients selected and I will tell you the results'. Respir Med 2006;100 Suppl. A:S17-21. Epub 2006 May 23
32. Herland K, Akelsen J, Skjønsberg, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger 'real life' population of patients with obstructive lung disease? Respir Med 2005;99:11-19
33. Chipps J, Spahn C, Sorkness L, et al. Variability in asthma severity in pediatric subjects widi asthma previously receiving short-acting β2-agonists. J Pediatr 2006;148:517-21B
34. Stempel DA, Stoloff SW, Carranza R, Jr., et al. Adherence to asthma controller medication regimens. Respir Med 2005;99:1263-7
35. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51
36. Tews JT, Volmer T. Differences in compliance between combined salmeterol/fluticasone propionate in the Diskus device and fluticasone + salmeterol given via separate Diskus inhalers. Am J Respir Crit Care Med 2002;165:A188
37. Marceau C, Lemiere C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol 2006,118: 574-81
38. O'Connor RD, Carranza Rosenzweig J, Stanford R, et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol 2005;95: 535-40
39. Delea TE, Hagiwara M, Stanford R, Stempel DA. Utilization and costs of asthma-related care in patients initiating fluticasone propionate/salmeterol combination, salmeterol, or montelukast as add-on therapy to inhaled corticosteroids. Data in preparation 2006
40. MHRA. Commission on Human Medicines. Salmeterol (Serevent) and formoterol (Oxis, Foradil) in asthma management. Curr Probl Pharmacovigilance 2006;31:6
41. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003;112:29-36
42. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/fluticasone propionate (50/250microg) combination is superior to double dose fluticsone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004;134:50-8 (SAS40009)
43. Bateman ED, Britton M, Carillo J, et al. Salmeterol/fluticasone propionate (50/100 mg) combination inhaler (Seretide). A new effective and well tolerated treatment for asthma. Clin Drug Invest 1998;16:193-201 (SFCB3017)
44. Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 mg) administered via combination Diskus inhaler: As effective as when given via s eparate Diskus inhalers. Can Respir J 1999;6:45-51 (SFCB3018)
45. Aubier M, Pieters WT, Schlosser NJJ, et al. Salmeterol/ fluticasone propionate (50/500 mcg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93:876-84 (SFCB3019)
46. Dahl R, Chuchalin A, Gor D, et al. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/ budesonide combinations in adults with persistent asthma. Respir Med 2006; 100:1152-62 (SAM40040)
47. Van den Berg NJ, Ossip MS, Hederos CA, et al. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Ped Pulm 2000;30:97-105 (SFCB3020)
48. Curtis L, Netten A. Unit Costs of Health and Social Care 2005. Personal and Social Services Research Unit, University of Kent. Available at htp://pssru.ac.uk/publications.htm (Accessed July 2006)
49. NHS Reference Costs. http://www.dh.gov.uk/assetRoot/ 04/10/55/61/ 04105561.xls. (accessed July 2006) 2004